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Hepatocellular carcinoma (HCC) is one of the most common
causes of cancer death worldwide. HCC can be cured by radical
therapies if early diagnosis is done while the tumor has remained
of small size. Unfortunately, diagnosis is commonly late when the
tumor has grown and spread. Thus, palliative approaches are usu-
ally applied such as transarterial intrahepatic chemoembolization
and sorafenib, an anti-angiogenic agent and MAP kinase inhibitor.
This latter is the only targeted therapy that has shown signiﬁcant,
although moderate, efﬁciency in some individuals with advanced
HCC. This highlights the need to develop other targeted therapies,
and to this goal, to identify more and more pathways as potential
targets. The Wnt pathway is a key component of a physiological
process involved in embryonic development and tissue homeo-
stasis. Activation of this pathway occurs when a Wnt ligand binds
to a Frizzled (FZD) receptor at the cell membrane. Two different
Wnt signaling cascades have been identiﬁed, called non-canoni-
cal and canonical pathways, the latter involving the b-catenin
protein. Deregulation of the Wnt pathway is an early event in
hepatocarcinogenesis and has been associated with an aggressive
HCC phenotype, since it is implicated both in cell survival, prolif-
eration, migration and invasion. Thus, component proteins iden-
tiﬁed in this pathway are potential candidates of pharmacological
intervention. This review focuses on the characteristics andJournal of Hepatology 20
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HCC represents a major public health problemwith a high impact
on society. HCC is the sixth most common tumor worldwide in
terms of incidence (about one million per year). Projections are
that this incidence will substantially increase during the next
decades due to persistent infection with the hepatitis C virus as
well as the emergence of non-alcoholic steatohepatitis as a major
health problem. HCC portends a poor prognosis since ranking
third in terms of ‘‘cause of death’’ by cancer, and often presents
as a major complication of cirrhosis related to chronic hepatitis
B and C infections, or non-virus related [1–3]. The dismal progno-
sis is generally related to a late diagnosis after HCC cells have
inﬁltrated the liver parenchyma, have spread through the portal
venous system and/or have formed distant metastases. However,
if HCC is diagnosed early (<20% of patients), these smaller tumors
may be cured by surgical resection, liver transplantation or radio-
frequency ablation. In more advanced tumors (>80% of patients at
diagnosis), only palliative approaches can be applied. In this
regard, transarterial intrahepatic chemoembolization has been
shown to be somewhat effective in increasing overall survival
of individuals with tumors that have spread only into the liver
parenchyma without extrahepatic metastasis (median overall
survival is increased from 15 to 20 months compared to the best
supportive care). In HCC with extrahepatic spread, only sorafenib,
an anti-angiogenic and MAP kinase inhibitor, has been shown to
increase overall survival of patients (from 8 to 11 months) [4]. All
other systemic approaches such as cytotoxic chemotherapy have
not been shown to be effective; thus, to date, no targeted therapy
except sorafenib has been proven to prolong life in patients with
HCC. However, there are ongoing or ended clinical trials with
agents that target FGF, VEGF, PDGF, EGF, IGF, mTOR, and TGFb
signaling pathways but none has been shown yet to have a signif-
icant impact on patient survival [5].13 vol. 59 j 1107–1117
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Recently, cancer stem cells (CSC) have been hypothesized to
play a key role in tumor maintenance as well as relapse after sur-
gical resection. There is accumulating information that supports a
role for CSC in hepatocarcinogenesis to maintain the tumor size
and to initiate tumor recurrence following therapy [6]. The pool
of CSC is maintained by self-renewal capabilities that are largely
driven by reactivation of embryonic signaling programs mediated
by Wnt, Notch, Bmi, and Hedgehog pathways, similar to what has
been previously demonstrated during breast carcinogenesis [7].
Preclinical studies further underline the potential value of inhib-
iting activation of these signaling programs in some tumor types
[8–11].
In this review, we describe the features of a therapeutic target,
i.e., the Wnt pathway, for potential therapy of HCC. We will dis-
cuss experimental and preclinical studies regarding the use of
Wnt inhibitors as a therapeutic approach for HCC.The Wnt-mediated signaling
The ﬁrst member of the Wnt family of ligands was identiﬁed
from the int-1 gene found in a mammary adenocarcinoma,
located at the integration site of the mouse mammary tumor
virus (MMTV); subsequently, it was demonstrated to have onco-
genic properties [12]. More important, int-1 homolog genes have
been found in human tumors as well [13]. In addition, a highly
conserved int-1 homolog was also discovered in Drosophila and
designated Wingless ‘‘Wg’’ [14]. The combination of int-1 and
Wingless led to the common Wnt1 terminology and recently
has been used to designate the Wnt family of ligands [15].
Wnt proteins are secreted extracellular auto-paracrine glyco-
proteins that interact with Frizzled receptors (FZD), a seven
transmembrane domain protein, resembling the G-protein-cou-
pled receptor (GPCR) family. Vinson and colleagues revealed that
FZD contains an extracellular cysteine-rich domain (CRD) which
is the putative binding site for the Wnt ligands. These investiga-
tors demonstrated the functional role of the frizzled locus to coor-
dinate development of the cytoskeleton in Drosophila epidermal
cells [16]. Subsequently, Wnt/FZD-mediated signaling has been
extensively studied, and although it has been widely implicated
in cellular homeostasis, these ligand/receptor interactions have
now been appreciated as key factors during the oncogenesis pro-
cess and therefore, could serve as new therapeutic targets.
Thus, Wnt proteins represent members of a highly conserved
family that is involved in several processes including embryonic
development, cell fate determination, proliferation, polarity,
migration, and stem cell maintenance. In addition, Wnt/beta-
catenin signaling has been found to play key roles in metabolic
zonation of adult liver, regeneration [17]. In adult organisms,
deregulation of Wnt signaling may lead to tumor development
[18,19]. The Wnt-mediated pathway is activated through the
binding of one Wnt ligand to a FZD receptor. Ten different FZD
receptors and 19 Wnt ligands have been identiﬁed in humans.
The binding of Wnt to an FZD receptor can trigger activation of
at least three different pathways. The ﬁrst is the Wnt/b-catenin
cascade, also called the Wnt-canonical pathway; the remaining
two are the planar cell polarity (PCP) and the Wnt/calcium path-
ways, respectively. The two latter are b-catenin independent and
represent examples of the non-canonical cascades. In this regard,
a multitude of combinations between the 19 Wnt ligands and the
10 FZD receptors, such as co-receptors and other molecules, are1108 Journal of Hepatology 2013theoretically possible. Classically, Wnt1/2/3/3a/8a/8b/10a/10b
and FZD1/5/7/9 are classiﬁed as the canonical elements, whereas
Wnt4/5a/5b/6/7a/7b/11 and FZD2/3/4/6 are designated as non-
canonical components. The remaining Wnt2b/9a/9b/16 and
FZD8/10 proteins remain unclassiﬁed [19,20]. However, it
remains elusive how selectivity between Wnt/FZD as well as
speciﬁcity of downstream signaling is achieved. Some Wnt/FZD
elements can share dual canonical and non-canonical functions.
For instance, it has been shown that in absence of Ror2 co-recep-
tors, Wnt5a can activate b-catenin signaling with FZD4 and Lrp5
[21]. FZD3 has been described to act likely through canonical
pathways in mice neurogenesis [21]. Zhang et al. demonstrated
that in Xenopus foregut, FZD7 can activate low level of b-catenin
and non-canonical JNK signaling in which both pathways contrib-
uted to foregut fate and proliferation while JNK pathway regu-
lated cell morphology [22]. It is of interest that canonical and
non-canonical pathways can not only be driven by speciﬁc
Wnt/FZD combinations, but also by cell type, differentiation sta-
tus, localization and composition of the microenvironment [23].
The canonical Wnt/FZD pathway
The b-catenin protein, encoded by the CTNNB1 gene, is a key com-
ponent of Wnt-canonical pathway signaling. b-catenin has a cen-
tral region which presents armadillo domain repeats important
for the binding of partners, such as Axin1 and adenomatous pol-
yposis coli protein (APC) as well as transcription factors [24]. The
C- and N-terminal regions are important. C-terminus of b-catenin
serves as a binding factor for a multitude of complexes promoting
b-catenin-mediated transcription, whereas phosphorylation of
the N-terminus promotes degradation of b-catenin. Indeed, b-
catenin may be present in several cellular compartments, such
as the inner plasma membrane having a role in cell-cell junctions,
the cytoplasm and the nucleus where it forms an active complex
containing TCF/LEF transcription factors (T-cell factor/lymphoid
enhancer factor) [25]. In the absence of nuclear b-catenin, TCF/
LEF interact with the transcriptional co-repressor transducin like
enhancer-1 (TLE-1) (Drosophila homolog Groucho), thus prevent-
ing b-catenin target gene expression [26]. Following translocation
into the nucleus, b-catenin binds to TCF/LEF and replaces the TLE-
1 repressor to form a transcriptional complex that activates the
expression of its target genes (Fig. 1).
In absence of the canonical Wnt signaling, cytosolic b-catenin
is targeted for degradation by a complex composed of a scaffold
of proteins named axin1, APC, and two serine/threonine kinases:
the glycogen synthase kinase 3b (GSK3b) and the casein kinase 1
(CK1) [27] (Fig. 1A). Axin1 and APC act together as scaffolding
proteins through binding of b-catenin, and enhance its N-termi-
nal phosphorylation by GSK3b and CK1. The ﬁrst phosphorylation
event is generated by CK1 at Ser45 which allows the GSK3b-med-
iated sequential phosphorylation of Thr41, Ser37, and Ser33
[28,29]. Ser37 and Ser33 phosphorylations provide a binding site
for the E3 ubiquitin ligase b-TRCP (b-transducin repeat contain-
ing protein), leading to b-catenin ubiquitination in a b-TRCP/
Skp1/cullin F-box complex (SCF) dependent manner followed
by proteasomal degradation [30,31].
Activation of the canonical Wnt signaling cascade leads to dis-
ruption of the b-catenin degradation complex, resulting in b-cate-
nin accumulation in the cytoplasm followed by translocation into
the nucleus where it serves as a transcription factor to activate
downstream target genes (Fig. 1B). In brief, this process is asvol. 59 j 1107–1117
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Fig. 1. Canonical Wnt/FZD signaling pathway. (A) In the absence of Wnt signaling, soluble b-catenin is phosphorylated by a degradation complex consisting of the kinases
GSK3b and CK1a and the scaffolding proteins APC and Axin1. Phosphorylated b-catenin is targeted for proteasomal degradation after ubiquitination by the SCF protein
complex. In the nucleus and in the absence of b-catenin, TCF/LEF transcription factor activity is repressed by TLE-1; (B) activation of the canonical Wnt/FZD signaling leads
to phosphorylation of Dvl/Dsh, which in turn recruits Axin1 and GSK3b adjacent to the plasma membrane, thus preventing the formation of the degradation complex. As a
result, b-catenin accumulates in the cytoplasm and translocates into the nucleus, where it promotes the expression of target genes via interaction with TCF/LEF
transcription factors and other proteins such as CBP, Bcl9, and Pygo.
JOURNAL OF HEPATOLOGYfollows: Wnt ligand binds to the extracellular domain of an FZD
receptor and Lrp5/6 co-receptors. This ternary complex (Wnt/
FZD/Lrp) recruits the scaffolding phosphoprotein dishevelled
(Dvl/Dsh) at the plasma membrane which in turn traps the
axin-bound-GSK3b complex, thus preventing proteasomal degra-
dation of cytosolic b-catenin. When stabilized, b-catenin is able to
translocate into the nucleus, where it binds to TCF/LEF transcrip-
tion factors and then forms a transcriptionally active complex
with pygopus (Pygo), CBP (CREB-Binding Protein) and Bcl9 pro-
teins [32]. In mammals, four TCF genes have been described,
which adds further complexity to the mechanism(s) of activation
of the Wnt canonical cascade [33]. Of notice is the b-catenin pool
localized at the plasma membrane that plays a key role in cell-Journal of Hepatology 2013cell junctions. To this aim, a complex including either p120 cate-
nin/c-catenin(plakoglobin)/a-catenin or p120 catenin/b-catenin/
a-catenin [25] binds to the cytoplasmic carboxyl terminus
domain of E-cadherin adhesion molecule, in order to join cadher-
ins to the actin cytoskeleton. More precisely, p120 catenin binds
to the juxtamembrane and then b-catenin or c-catenin binds to
the cytoplasmic domain of E-cadherin. The remaining a-catenin
serves as a link between actin and b/c-catenin which leads to
the stabilization of cell adhesion [34]. The possible consequences
of inhibiting b-catenin at adherent junctions have to be discuss in
respect of their role in epithelio-mesenchymal transition (EMT).
Disruption of E-cadherin-mediated adherent junctions is a major
event in EMT [35] and because of the interplay betweenvol. 59 j 1107–1117 1109
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cadherin-mediated cell adhesion and canonical/b-catenin signal-
ing [36], targeting b-catenin could also promote the disruption of
these junctions leading to enhance EMT. However, Wickline et al.
have shown that in hepatocyte-speciﬁc b-catenin-conditional
null mice, c-catenin is upregulated and associated with E-cad-
herin and actin to maintain adherent junctions. In addition, no
nuclear c-catenin was detected in liver of KO mice, leading to
the conclusion that despite armadillo domains on c-catenin,
there is no compensation at nuclear level. Nevertheless, authors
warn us about preventing concurrent c-catenin suppression that
may increase tumor cell invasion [37]. More recent study con-
ﬁrmed these results in in vitro experiments with HCC cell lines
and identiﬁed the mechanism of c-catenin stabilization as ser-
ine/threonine phosphorylation induced by protein kinase A
[38]. With regard to this recent data, targeting b-catenin in HCCFZD
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Fig. 2. Non-canonical Wnt/FZD signaling pathways. Interaction of Wnt, FZD, and ROR2
transactivation, or (4) inhibition of b-catenin activity through binding of NLK to TCF/LE
1110 Journal of Hepatology 2013therapies may not disturb cell junctions since the design of
Wnt inhibitors for therapeutic intervention, speciﬁcally desig-
nates soluble active b-catenin as preferential target.
The non-canonical Wnt/FZD pathways
In contrast to the canonical Wnt pathway, non-canonical signal-
ing does not depend on b-catenin and requires Ror2/Ryk co-
receptors instead of Lrp5/6 (Fig. 2). In the Wnt/PCP pathway,
Wnt/FZD interaction promotes the recruitment of Dvl/Dsh, which
in turn binds to the small GTPase protein called Rac, leading to
both the induction of ROCK (Rho-associated protein kinase) path-
way and the activation of the MAP kinase cascade and subse-
quently to the activation of AP1-mediated target gene
expression [39,40]. In the Wnt/calcium pathway, the complexP
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Table 1. Most prevalent potential mechanisms involved in activation of beta-
catenin found so far in HCCs.
Mechanism Prevalence in HCC tissues
CTNNB1 mutation 8-30%
AXIN mutation 8-15%
APC mutation 1-3%
FZD7 overexpression 23-59%
WNT3 overexpression 35-42%
sFRP1 repression 44-60%
sFRP5 repression 21-35%
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formation between FZD, Dvl/Dsh and G proteins results in PLC
(Phospho Lipase C) activation which cleaves PIP2 (Phosphatidyl
Inositol 4,5 biphosphate) into DAG (DiAcylGlycerol) and IP3
(Inositol 1,4,5-triphosphate). This process results in the activation
of PKC (Protein Kinase C) through DAG while IP3 promotes
calcium release from the endoplasmic reticulum. Increased intra-
cellular concentration of calcium enhances phosphorylation and
activation of PKCs. This also triggers the activation of Ca2+-cal-
modulin-dependent calcineurin and CAMKII (Ca2+-calmodulin
dependent kinase II), leading to NFAT (Nuclear Factor of Activated
T-cell) and NLK (Nemo Like Kinase) translocation, respectively.
NLK acts as a b-catenin pathway inhibitor through phosphoryla-
tion and degradation of TCF/LEF transcription factors [41].
Antagonists and agonists of Wnt/FZD-mediated signaling
Several secreted proteins are known to negatively or positively
regulate the Wnt/FZD complex. Four classes of antagonistic mol-
ecules have been described. Wnt inhibitory protein-1 (Wif1) and
secreted FZD-related proteins (sFRP1, 2, 3, 4, 5) bind to and
sequester the soluble Wnt ligands, thus inhibiting their interac-
tion and binding to FZD receptors [42–45]. The Dickkopf family
is composed of four members (Dkk1, 2, 3, 4) that can interact
with both Lrp5/6 and Krm1,2 (Kremen1,2) co-receptors [46].
The ternary complex Lrp-Dkk-Krm prevents b-catenin stabiliza-
tion by promoting Lrp5/6 endocytosis [47]. Wise and Sost pro-
teins form the other class of secreted antagonists. They bind to
Lrp5/6 and thus disrupt the Wnt-induced FZD-Lrp5/6 interaction
[48,49].
Three agonistic molecules have recently been identiﬁed; the
R-spondins (Rspo1, 2, 3, 4), norrin and glypican-3 (Gpc3). The
Gpc3 is a heparan sulfate proteoglycan bound to the cell mem-
brane through a glycosyl-phosphatidylinositol anchor. Gpc3
increases autocrine/paracrine canonical Wnt signaling by binding
to Wnt ligands, thus facilitating the interaction between Wnt
ligands and FZD receptors [50]. Mechanisms by which Rspo and
Norrin activate the canonical Wnt pathway have not been clari-
ﬁed. Rspo1 is able to bind to both Lrps and FZDs but it has also
been proposed that Rspo prevents Lrp6 internalization through
binding to Krm instead of Dkk [51–53].Wnt signaling deregulation in human hepatocarcinogenesis
Similar to other tumor tissue types, the canonical Wnt/FZD
signaling is a critical contributor to HCC pathogenesis. Indeed,
40–70% of HCCs harbor nuclear accumulation of the b-catenin
protein, one of the hallmarks of the Wnt/b-catenin pathway
activation [54–56]. Activating mutations of the b-catenin gene
(CTNNB1) occur in 8–30% of tumors, while loss-of-function/
mutations in APC and Axin genes occur in 1–3% and 8–15%,
respectively and are mutually exclusive to CTNNB1 mutations
[54,57–62]. Some observations suggest that the CTNNB1mutation
could be a late event during hepatocarcinogenesis. However,
accumulation of b-catenin was detected in the early stage of
HCC development, suggesting that other mechanisms could con-
tribute to b-catenin stabilization (Table 1) [60,63]. Strikingly,
extrinsic activation of Wnt/b-catenin pathway and CTNNB1muta-
tion do not lead to the same molecular expression pattern, sup-
porting different roles for wild type and mutated b-catenin. The
Wnt/b-catenin activated HCC subclass with a CTNNB1 mutation
is characterized by upregulation of liver-speciﬁc Wnt-targets,Journal of Hepatology 2013low grade and well-differentiated tumors, with chromosome sta-
bility and a favorable prognosis. The Wnt/b-catenin activated
HCC subclass without CTNNB1 mutation is characterized by dys-
regulation of classical Wnt targets, high chromosomal instability,
aggressive phenotype, and is preferentially associated with
chronic HBV infection [54,63,64].
Modulation of Wnt ligands or FZD receptor expression could
account for Wnt/b-catenin pathway activation without any other
mutations in CTNNB1, APC, or Axin genes. Indeed, upregulation of
activators, such as ligands (Wnt1/3/4/5a/10b) or receptors/co-
receptors (FZD3/6/7, Lrp6), and downregulation of inhibitors
(sFRP1/4/5, Wif1, Dkk3, Dkk4) have been reported both in HCC
tumors and surrounding precancerous liver tissues, which
emphasizes that their over and/or underexpression may be early
molecular events during hepatocarcinogenesis [65–73].
Although b-catenin activation is crucial for liver development
and regeneration, it is not sufﬁcient per se for initiation of hepato-
carcinogenesis. Indeed, animal models overexpressing an active
b-catenin protein do not spontaneously form HCC [74–76]. How-
ever, b-catenin activation may cooperate with other oncogenic
pathways such as insulin/IGF-1/IRS-1/MAPK, H-RAS, MET, AKT
and chemicals to induce HCC formation in mice [75,77–79]. It
is described that beta-catenin mutation is a late event in hepato-
carcinogenesis since present in some HCC tumors whereas absent
in preneoplastic lesions, thus prompting us to speculate that only
non-mutated beta-catenin could play a role in very early steps of
hepatocarcinogenesis such as initiation and promotion. However,
mutated forms of beta-catenin are used in experimental models
to assess the role of activated beta-catenin in hepatocarcinogen-
esis. In these experimental mouse models, it is well shown that
mutated beta-catenin is insufﬁcient alone and per se for initiation
of HCC but only enhance tumor promotion either in a context of
chromosomal instability and increase of susceptibility to DEN-
induced HCC formation [78,80], or in a context of Lkb1+/ mice
that spontaneously develop multiple hepatic nodular foci (NdFc)
followed by HCC [81], or in a context of H-Ras transgenic mice
where mutated beta-catenin appears as a strong carcinogenic
co-factor collaborating with the mutated Ras oncogene [82]. In
contrast and apparently paradoxically, invalidation of beta-cate-
nin in hepatic beta-catenin conditional knockout mice has been
found as enhancing DEN-induced tumorigenesis [83]. Of interest
is another model of HCC developing in mice under exposure to
phenobarbital (PB, potent tumor promoter in mouse liver) and
DEN as tumor initiator. A tumor initiation–promotion study
was conducted in mice with conditional hepatocyte-speciﬁc
knockout (KO) of Ctnnb1 and in Ctnnb1 wild type controls. Asvol. 59 j 1107–1117 1111
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expected, DEN + PB strongly enhanced liver tumor formation in
Ctnnb1 wild type mice. Amazingly, the prevalence of tumors in
Ctnnb1 KO mice was 7-fold higher than in wild type mice, sug-
gesting an enhancing effect of the gene KO on liver tumor devel-
opment [84]. Thus there is a paradox where the absence of wild
type beta-catenin or presence of the mutated form, both lead to
enhanced DEN-induced hepatocarcinogenesis. The issue is that
the discussion is speculative since the mechanism of increased
HCC in conditional beta-catenin KO is unknown. In the design
of Wnt inhibitors for therapeutic intervention, these agents do
target the Wnt pathway through the soluble beta-catenin cas-
cade, but do not impact on invalidation of the beta-catenin pool
involved in the membrane catenin/cadherin complexes involved
in cell homeostasis. The beta-catenin therapeutic targeting may
need to be personalized, based on the unexpected ﬁndings of
enhanced tumorigenesis after chemical exposure in hepatocyte-
speciﬁc beta-catenin conditional knockout mice.
Although the role of Wnt/b-catenin pathway is debated with
respect to the initiation of hepatocarcinogenesis, it is deﬁnitively
implicated in determining HCC aggressiveness, due to its promo-
tion of increased cell proliferation, migration and invasion. This
ﬁnding has been further substantiated by ectopic expression of
Wnt3 and FZD7, Lrp6 or downregulation of sFRP1, Dkk1 and
Dkk4 in HCC cell lines [66,69,73,85,86]. Moreover, recent studies
have revealed that the Wnt/b-catenin pathway is also involved in
the self-renewal and expansion of HCC initiating cells (i.e., the so-
called liver CSC) which also inﬂuences tumor aggressiveness and
resistance to chemo- radio-therapeutic agents [87,88]. Further-
more, Wnt/FZD-mediated signaling could inﬂuence tumor micro-
environment that supports tumor survival, growth, and size.
Recent investigations emphasize the role of sFRP1 in the induc-
tion of senescence of tumor-associated ﬁbroblasts after chemo-
therapeutic treatment [89–91].
It is noteworthy that the canonical and non-canonical Wnt/
FZD pathways may have complementary roles in the pathogene-
sis of HCC. Indeed, b-catenin activation appears to be involved in
the tumor initiation phase of hepatic oncogenesis, whereas sub-
sequent activation of non-canonical pathways associated with
inactivation of b-catenin may enhance tumor promotion and pro-
gression [88]. However, non-canonical pathways can also exhibit
opposite effects on tumor behavior, since speciﬁc Wnt/FZD com-
binations are able to function as tumor suppressors [92].
Although little is known about the role of Wnt/PKC pathway in
HCC, it has been demonstrated that inhibition of PKCb activity
reduces motility and invasion properties of HCC cells [93]. Finally,
activation of the Wnt/JNK pathway during HCC progression
would presumably support tumor growth, since enhanced JNK
activity appears to be involved in HCC cell proliferation both
in vitro and in vivo [94].
Identiﬁcation of molecular targets for therapeutic
interventions
There is some evidence to link the Wnt pathway activation to
tumor cell properties characteristic of the malignant phenotype,
such as enhanced cell proliferation, migration and invasion,
which raises the possibility to target members of this signaling
cascade as an attractive therapeutic approach for treatment of
HCC [95,96] (Fig. 3).1112 Journal of Hepatology 2013Targeting extracellular molecules of the Wnt pathway
Antibody-based therapies directed against the overexpressed
Wnt ligands and FZD proteins could provide a therapeutic
approach. For instance, preclinical experiments have shown that
an anti-Wnt1 monoclonal antibody inhibits the Wnt signaling
pathway resulting in enhanced apoptosis and inhibiting cell
proliferation, both in vitro and in vivo in a xenograft model of
HCC [67]. These ﬁndings have been experimentally validated
for several other types of tumors, such as sarcomas, colon,
breast, non-small-cell lung cancer, and head-neck squamous cell
carcinomas [97–100]. Interestingly, as demonstrated with a
colon cancer cell line, this anti-Wnt antibody was able to induce
apoptosis even in the presence of downstream mutations in APC
or CTNNB1 genes and appeared to be synergistic with docetaxel
chemotherapy with respect to therapeutic response [97].
Although not tested in HCC tumors thus far, anti-Wnt2 antibod-
ies may be useful to inhibit the Wnt/b-catenin cascade. Such
antibodies induce apoptosis and inhibit tumor growth in vivo
in several tumor types, including melanoma, mesothelioma,
and non-small-cell lung cancer [101–103]. Since non-canonical
pathways seem to be implied in tumor progression, the inhibi-
tion of Wnt-related ligand could be considered for therapy. For
instance, WNT5A, which seems to be involved in the non-canon-
ical pathway in HCC [88], could be antagonized by the use of
anti-WNT5a antibodies. Indeed, in gastric cancer cells where
WNT5A activates the non-canonical pathway, its inhibition
reduces migration and invasion activities in vitro and in vivo
[104]. Nevertheless, since the non-canonical pathway could
antagonize the canonical one, it might be deleterious to inhibit
the former. Anti-FZD7 antibodies that induce apoptosis and
decrease cell proliferation both in vitro and in vivo of FZD7 posi-
tive Wilms’ tumor cells are also available [105]. More recently, a
multispeciﬁc antibody that targets both FZD 1, 2, 5, 7, and 8 and
mainly affects the canonical signaling pathway has been devel-
oped. It triggers a therapeutic reduction of breast, colon, lung
and pancreas tumor growth and synergizes with other chemo-
therapeutic agents as well [106]. Strikingly, this antibody
remains effective even in tumor cells with APC or CTNNB1 gene
mutations. In addition, FZD co-receptors could also be attractive
targets for monoclonal antibody therapy since, in a retinal pig-
ment epithelial cell line, anti-Lrp6 antibody has been shown
to inhibit Wnt signaling [107].
Another therapeutic strategy would be to trap the endoge-
nous Wnt ligands with the exogenous soluble form of FZD
receptors. This approach was reported for FZD7 by Tanaka and
colleagues in esophagus carcinoma cells and conﬁrmed later in
HCC cells [86,108]. More recently, Wei and co-workers have
developed the same approach using an FZD7 extracellular
domain peptide (sFZD7) that can bind to and sequester the sol-
uble Wnt3 ligand. This peptide decreased the viability of HCC
cell lines with high speciﬁcity, since normal hepatocytes were
not sensitive to sFZD7. Moreover, sFZD7 cooperates with doxo-
rubicin to reduce HCC cell proliferation in vitro and in a xeno-
graft murine model as well. Interestingly, it has been shown
to be highly efﬁcient and independent of the b-catenin muta-
tional status [109]. Inhibition of Wnt secretion by the small
molecules, IWP2 and Wnt-C59 may also prevent autocrine
Wnt signaling activation, as observed in colon cancer cell lines.vol. 59 j 1107–1117
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5. Inhibit β-catenin/co-factors interactions
FH535, PKF115-584, PKF118-310, CGP049090,
ICG-001, PRI-724
Fig. 3. Potential Wnt-component targets for therapeutic intervention on tumor development and growth. Inactivation of Wnt signaling pathway could be achieved
by: (1) targeting extracellular signaling molecules with monoclonal antibodies, soluble factors or small molecules; (2) preventing the FZD/Dvl interaction; (3) stabilizing the
destruction complex or (4) increasing b-catenin proteasomal degradation and (5) preventing the interaction between b-catenin and its co-factors for transactivity in the
nucleus. The relationship between therapeutic molecules and their protein targets is indicated by a color code. Molecules in bold have been tested in HCC model, those in
italics in other models of tumor growth.
JOURNAL OF HEPATOLOGYThese small molecules are also able to inhibit the progression of
mammary tumors in Wnt1 transgenic mice [110,111]. Addition
of Wnt antagonist, such as sFRP1 or Wif1, has shown encourag-
ing therapeutic results in HCC cell lines by blocking the Wnt/b-
catenin signaling. These soluble molecules induce apoptosis,
reduce angiogenesis and cell proliferation both in vitro and
in vivo and are not inﬂuenced by the CTNNB1 mutation status
[112]. Other Wnt antagonists such as sFRP2 and sFRP5 should
also be considered, since they show similar treatment effectsJournal of Hepatology 2013in colon cancer as sFRP1 exhibits in HCC [113]. Interestingly,
Dkk1 and sFRP1 addition cooperates with anti-FZD7 antibodies
to increase apoptosis in Wilm’s tumor demonstrating the impor-
tance of combinatorial therapies [105]. Therapeutic small mole-
cules, such as niclosamide and silibinin, display anti-tumor
activity in vitro and in vivo by suppressing Lrp6 expression, lead-
ing to inhibition of Wnt/b-catenin signaling in human prostate
and breast tumor cells, as well as by promoting induction of
apoptosis [114,115].vol. 59 j 1107–1117 1113
Review
Targeting the Wnt-mediated pathway in the cytosol
The straight-in approach to inhibit Wnt/b-catenin pathway is to
directly target b-catenin by small interfering-RNA or antisense
based therapy, which can reduce cell proliferation and survival
of HCC cell line, providing a proof of principle for this approach
[116–118]. However, its potential use as a therapeutic tool
remains unlikely since b-catenin protein is essential for cell junc-
tion. Thus, targeting the soluble active pool of b-catenin seems
more appropriate.
The interaction between the cytosolic tail of FZD and its
adaptor Dvl protein is of importance in mediating Wnt signal-
ing. A proof-of-principle has clearly been established in HCC
cells, by using small interfering peptides capable of entering
the tumor cells and disrupting the interaction between a spe-
ciﬁc motif on the FZD7 cytosolic tail and the PDZ domain of
Dvl [11]. Similar results have been obtained in melanoma and
non-small-cell lung cancer cells with small molecules using this
same strategy [119].
Targeting the b-catenin destruction complex (APC, Axin, CK1,
and GSK3b) as a therapeutic target has not been assessed in
HCC so far. However, using other tumor model systems, such
a strategy has demonstrated some potential. Since Axin1 over-
expression induces apoptosis in HCC harboring APC, Axin1 or
CTNNB1 mutations, stabilization of Axin1 would be an attractive
approach to trigger b-catenin degradation [120]. This may be
achieved by using inhibitors of the Axin1 or/and 2 degradation,
such as the smalls peptides IWR2, JW55 or XAV939 that inhibit
the Wnt/b-catenin pathway, leading to a decreased proliferation
of colon and breast cancer cell lines. Nevertheless, recent ﬁnd-
ings support the idea that this decrease may be restricted to
low nutriment conditions, and emphasizes that stabilization of
Axin needs to be combined with other therapeutic approaches
[110,121–123]. Preventing b-catenin stabilization through
GSK3b activation would also be possible due to the discovery
of differentiation-inducing factors (DIFs), which are natural
metabolites expressed by Dictyostelium discoideum. Although
the mechanisms of action of DIFs activity remain poorly under-
stood, it is well known that DIFs induce b-catenin degradation
and subsequently reduce cyclin D1 expression and function
[124]. CK1a, another component of the destruction complex,
may be stabilized by pyrvinium that inhibits both Wnt signaling
and cell proliferation, even in the presence of APC or CTNNB1
mutations, as observed in colon cancer cell lines [125]. Another
therapeutic approach would be to enhance b-catenin proteaso-
mal degradation. In HCC, colon and prostate cancer cell lines,
the small molecule antagonist CGK062 has been shown to exert
such an effect, via the induction of b-catenin phosphorylation in
the N-terminal domain which promotes its degradation [126].
Two chemicals agents, hexachlorophene and isoreserpine,
upregulate Siah-1, an ubiquitin ligase that induces b-catenin
degradation, independent of its phosphorylation status, thereby
inhibiting Wnt signaling and subsequently has been shown to
reduce colon cancer cell proliferation [127].
Targeting the Wnt pathway in the nucleus
Finally, an alternative way to block Wnt-mediated signaling is
to target the nuclear b-catenin per se and/or the co-factors
responsible for transcription of downstream Wnt-responsive1114 Journal of Hepatology 2013genes. To accomplish this aim, several small molecules have
been identiﬁed. The FH535 agent prevents both Wnt- and PPAR-
(Peroxisome Proliferator-Activated Receptors) mediated signal-
ing by suppressing the recruitment of b-catenin co-activators
to target gene promoters and has been shown to be active in
HCC, colon, and lung tumor cell lines [128]. PKF115-584,
PKF118-310, and CGP049090 are inhibitors of TCF/b-catenin
binding to DNA target sequences. They induce apoptosis
in vitro and in vivo, as well as cell cycle arrest at the G1/S phase
and suppress tumor growth in vivo independently of the
mutated status of CTNNB1 [129]. Furthermore, inhibition of b-
catenin/CBP interaction by ICG-001 both selectively induces
apoptosis in transformed, but not in normal colonic cells and
reduces growth of colon carcinoma cells in vitro as well as
in vivo [130]. A second generation ICG-001 (PRI-724) is also
available and in phase-I clinical trial (http://clinicaltrials.gov/
show/NCT01302405). Other b-catenin binding proteins such as
TBP, Bcl9, and Pygo also represent attractive approaches for
inactivating Wnt signaling. Finally, interferon can inhibit b-cate-
nin signaling through upregulation of RanBP3 that is a nuclear
export factor, serving as extruding b-catenin outside the nucleus
[131].Conclusions and perspectives
Developmental regulated signaling pathways, such as Notch,
Hedgehog and Wnt, have become important targets for new
cancer drug development. While Notch and Hedgehog inhibitors
are already in clinical trials, the Wnt inhibitors are still under
preclinical assessment and only a few compounds have started
to reach the phase-I clinical trials, since only recently has this
pathway been recognized as playing a key role in tumor devel-
opment. However, many studies have established proof-of-prin-
ciple that speciﬁc targeting of molecules in this pathway can
partially or fully switch off canonical as well as non-canonical
Wnt signaling and lead to substantial anti-tumor activity. Thus,
biotechnology and pharmaceutical organizations are currently
developing Wnt signaling inhibitors. These inhibitors can target
upstream or downstream proteins in this pathway. Targeting
the Wnt cascade upstream of APC is controversial because
downstream activating mutations in APC would, in theory, still
drive tumor development. To cover the broadest number of acti-
vating mutations that occur in tumors, it seems that the ideal
antagonist would be one that exerts its anti-tumor effect in
the nucleus. Nevertheless, several experiments show that
upstream targeting can also be very effective. Of importance is
the potential toxicity of Wnt inhibitors on normal cells. Indeed,
the Wnt pathway is critical for tissue and liver regeneration and
for the ability of stem cells to self-renewal. Wnt pathway inhib-
itors could therefore have substantial and long-term side effects
including anemia, immune suppression, as well as damage of
the gastrointestinal tract. It is unknown what may occur in an
adult mammal when this pathway is shut down or reduced in
normal activity. Despite these known and unknown pitfalls,
drug development is moving steadily forward to generate and
characterize Wnt pathway inhibitors both in vitro and in vivo.
Indeed, agents that inhibit Wnt/b-catenin signaling as a means
to produce anti-tumor effects are currently being assessed in
clinical trials.vol. 59 j 1107–1117
Key Points
• The increasing incidence of HCC and the frequent
ineligibility of patients for curative options, due to 
a widespread dissemination of cancerous cells at
diagnosis, highlight the urgent need for effective 
systemic therapies.  Cytotoxic chemotherapy has
never shown significant efficiency so far, and targeted
therapies are under evaluation
  
• Thus far, only sorafenib (anti-angiogenic agent and
MAPK inhibitor) has brought significant benefit to
survival but the outcome of patients still remains poor
• Innovative targeted therapies onto oncogenic addiction
loops involved in HCC tumor aggressiveness and
maintenance are an attractive strategy. Among
them, the Wnt pathway might play a central role via
transactivity of β-catenin 
• Pharmacological inhibitors of the Wnt pathway are
under investigation, and identification of the key targets
in the complex network of Wnt components remains
a challenge.  Among them, Wnt ligands, frizzled 
receptors and β-catenin appear as the most evident
targets 
• The development of Wnt inhibitors has not reached
clinical trials thus far, but preclinical studies have given
promising results  
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